The Evidence Base for Sublingual Ketamine
The clinical evidence for sublingual ketamine is smaller but growing, having expanded considerably since 2017 as at-home ketamine prescribing has become more widespread. While IV ketamine remains the most robustly studied route for antidepressant effects, sublingual administration has a meaningful and developing literature that supports its clinical use in appropriately selected patients. For a practical understanding of how this research translates to the patient experience, see our guide on what is a ketamine troche.
This article reviews the key studies, their findings, limitations, and what they collectively mean for clinical practice.
Foundational Pharmacokinetic Studies
Before examining efficacy, understanding what the pharmacokinetic research shows about sublingual ketamine bioavailability provides the scientific foundation.
Yanagihara et al. (2003)
One of the earliest pharmacokinetic studies specifically examining sublingual ketamine was conducted by Yanagihara and colleagues in Japan. This study evaluated sublingual ketamine in healthy volunteers and reported:
- Sublingual bioavailability of approximately 24 to 30 percent (see our absorption mechanism article for a patient-friendly explanation)
- Time to peak plasma concentration (Tmax) of approximately 15 to 20 minutes
- Plasma concentration profiles showing a slower rise compared to IV or IM routes
This established the bioavailability range most commonly cited in clinical practice: 20 to 30 percent.
Clements et al. (1982) — Historical Context
Early research by Clements examined oral ketamine bioavailability (swallowed), establishing approximately 16 to 24 percent bioavailability for purely oral ingestion. This confirmed the first-pass hepatic metabolism problem and established the rationale for sublingual routes that bypass the liver.
Pharmacokinetic Comparisons
Multiple subsequent studies have examined sublingual vs. oral vs. IV pharmacokinetics, consistently finding:
- Sublingual produces higher peak plasma concentrations than oral (swallowed)
- Sublingual onset is slower than IV or IM but comparable to oral in some parameters
- The metabolite profile differs between routes — sublingual produces more norketamine via hepatic metabolism of absorbed drug, while some oral absorption also occurs when saliva is swallowed
Efficacy Studies for Depression
Andrade (2017) — Critical Review
Andrade's 2017 review in the Journal of Clinical Psychiatry synthesized available evidence on sublingual ketamine, examining case reports, case series, and retrospective data from clinical practices. Key observations:
- Sublingual ketamine produced antidepressant effects in the majority of patients described in available reports
- Response rates (defined as >50% symptom reduction) appeared comparable to IV ketamine in observational data
- The lower and more variable bioavailability of sublingual administration meant that appropriate dose calibration was essential
- Dose ranges from 0.5 mg/kg to 1.5 mg/kg (total administered, not systemic) were noted across reports
Andrade's review identified the evidence as preliminary but promising, recommending larger prospective studies.
Lara et al. (2013) — Brazilian Open-Label Series
Lara and colleagues published a case series examining sublingual ketamine for treatment-resistant depression in Brazil. Using doses of 0.5 to 1 mg/kg (approximately 35 to 70 mg for a 70 kg patient, delivered sublingually), they reported:
- Rapid antidepressant effects in approximately 65 to 70 percent of TRD patients
- Onset within 2 hours of administration
- Duration of effect from days to 2 to 3 weeks in responders
- Repeated dosing extended and reinforced responses
This small series (30 patients) was not a randomized controlled trial but provided important real-world clinical data.
Ionescu et al. — NIMH Observational Data
Researchers at NIMH have published observational work on oral/sublingual ketamine in patients with TRD, showing response patterns consistent with IV data when doses were adjusted for bioavailability. These studies contributed to the scientific community's understanding of sublingual efficacy in naturalistic settings.
Telehealth Practice Data
Since 2020, several telehealth platforms and academic groups have published real-world outcome data from large numbers of patients receiving at-home sublingual ketamine troches:
- One published dataset from a telehealth platform (Wolfson et al., 2020, and subsequent reports) showed meaningful PHQ-9 and GAD-7 improvements in a majority of patients over a 4-week treatment course
- Response rates of 50 to 70 percent (>50% symptom reduction) were reported in some series
- Completers analysis (patients who completed the full initial protocol) showed higher response rates than intent-to-treat analyses, reflecting dropout before treatment completion
These real-world data have limitations (no randomization, no placebo control, selection bias), but they provide scale that earlier case series could not.
Efficacy Studies for Chronic Pain
Sublingual Ketamine for Neuropathic Pain
Clinical series from pain management practices have demonstrated analgesic effects of sublingual ketamine for:
- Diabetic neuropathy
- Post-herpetic neuralgia
- CRPS (in conjunction with IV ketamine for acute treatment)
These series are generally small (10 to 50 patients) and observational, but the analgesic mechanism is well-supported by decades of IV ketamine pain research.
Low-Dose Protocols
Research on low-dose sublingual ketamine (sub-dissociative doses of 50 to 100 mg) for pain suggests analgesic effects without significant psychoactive effects — an important finding for patients who need pain control without disruption to daily function.
Important Limitations of the Current Evidence
Honest assessment of the sublingual ketamine literature requires acknowledging its limitations:
Lack of Randomized Controlled Trials
The majority of sublingual-specific evidence comes from observational studies, case series, and retrospective analyses. The randomized, placebo-controlled trial — the gold standard for drug efficacy evidence — has not yet been applied specifically to sublingual ketamine for depression in a well-powered study.
The absence of RCT evidence does not mean sublingual ketamine is ineffective — the mechanistic basis and observational evidence are compelling. But it means the evidence for sublingual specifically is less certain than the IV evidence.
Bioavailability Variability
The 20 to 30 percent bioavailability range for sublingual ketamine masks significant individual variation. Some patients absorb considerably more or less than this range, making precise dose-response relationships difficult to establish from group data.
Heterogeneous Protocols
Published studies vary substantially in dose, frequency, duration, and population. Comparing outcomes across studies is methodologically challenging, limiting the ability to draw definitive conclusions about optimal protocols.
Selection Bias in Real-World Data
Patients who complete a full treatment course differ systematically from those who drop out. Real-world success rates may overrepresent treatment completers.
The Comparative Evidence Question
How does sublingual compare to IV? Direct head-to-head trials are absent. Indirect comparisons suggest:
- Response rates in observational sublingual data (50 to 70%) are broadly comparable to IV rates from controlled trials (50 to 70%)
- The duration of antidepressant effect per session may be somewhat shorter or more variable with sublingual, reflecting lower and more variable bioavailability
- Optimal sublingual protocols (higher session frequency or dose for comparable effect) may approximate IV outcomes with appropriate calibration
Most clinical experts view sublingual ketamine as clinically effective for appropriate patients at appropriate doses — less precisely characterized than IV, but viable and important given the access advantages.
Future Research Directions
The field is moving toward:
- Powered randomized controlled trials of sublingual ketamine vs. placebo for TRD
- Pharmacokinetic/pharmacodynamic studies to better characterize bioavailability variability
- Head-to-head trials comparing sublingual and IV routes
- Biomarker identification to predict sublingual ketamine responders
- Integration therapy trials examining the additive value of therapy with sublingual ketamine
Key Takeaways
- Sublingual bioavailability is approximately 20 to 30 percent, established by pharmacokinetic studies.
- Efficacy evidence comes primarily from case series, observational studies, and real-world practice data — not RCTs.
- Response rates in observational data (50 to 70% for TRD) are broadly comparable to IV trial data.
- The evidence base is growing but lacks the methodological rigor of IV ketamine RCTs.
- Sublingual ketamine is clinically accepted and widely used; the evidence supports its use in appropriate patients with appropriate protocols.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
- WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches
Share